Repros skids on submission delay for Androxal NDA

Repros Therapeutics Inc. (NASDAQ:RPRX) fell $6.57 (28%) to $17.12 on Wednesday after the company said it will not submit an NDA to FDA for Androxal enclomiphene to treat secondary hypogonadism until possibly 4Q14. In September, Repros said it was on track to submit an NDA for the trans-isomer of clomiphene citrate in mid-2014 (see BioCentury Extra, Sept. 17) . ...